Molecular Biology of RV-C and its Asthma-related Receptor, CDHR3
RV-C 及其哮喘相关受体 CDHR3 的分子生物学
基本信息
- 批准号:10327681
- 负责人:
- 金额:$ 40.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-21 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAllergicAntibodiesAntibody DiversityAntibody ResponseAsthmaB cell repertoireBindingBiological AssayBirthBlood specimenCOVID-19COVID-19 surveillanceChildChildhoodCohort StudiesCommon EpitopeCoronavirusCountryDataDevelopmentDisease OutbreaksEnrollmentEpitopesFamilyFarming environmentFutureHumanHypersensitivityImmuneImmune systemIndividualInfantInfectionLaboratoriesLifeLung diseasesMachine LearningMicrobeMolecular BiologyMonitorMorbidity - disease rateNosePatternPeripheral Blood Mononuclear CellPopulationPredispositionPreventionProteomeRhinovirusSARS-CoV-2 infectionSerologySerumSeveritiesSeverity of illnessSocietiesSpecimenSymptomsTestingVaccine DesignViralViral AntibodiesViral Structural ProteinsVirusWisconsinburden of illnesscohortcostcross reactivityimmunogenicinfection risknew technologynovel coronavirusparent grantpublic health emergencyreceptorrespiratoryrespiratory virusresponsestudy populationsurveillance study
项目摘要
The new coronavirus outbreak that begin in December 2019 has created a global public health emergency. This
has led to an intense search to identify factors that contribute to the susceptibility and severity of illness. We
recently developed an array to identify antibody-binding epitopes for rhinoviruses. Data from these arrays can
be combined with information about viral protein structure to identify highly immunogenic regions for respiratory
viruses. We propose to expand this array to include linear epitopes that represent the entire proteome of SARS-CoV-2 and all other common coronaviruses that infect humans (OC43, NL63, etc.). The study population will
include children from the COAST, WISC and URECA birth cohort studies who are also participating in the
HEROS SARS-CoV-2 surveillance study. As part of routine cohort activities, these children undergo serial
sampling of blood and nasal secretions that we can analyze using the array to determine individual patterns of
antiviral antibody epitope recognition. We hypothesize that the pattern and quantity of antibody specific for
epitopes of common coronaviruses contributes to the susceptibility to SARS-CoV-2 infection and illness. We
propose three specific aims that will utilize sera obtained from children before and after HEROS-confirmed
infection with SARS-CoV-2. First, in specimens obtained pre-infection we will use the array to identify patterns
of antibody epitope recognition to common childhood coronaviruses, assess cross-reactivity with SARS-CoV-2,
and determine whether cross-reactivity is associated with protection against infection or illness. In the second
aim, we will determine whether the diversity of antibody responses to common respiratory viruses is associated
with a reduced risk of infection or illness. Finally, in the third aim we will describe antibody binding patterns before
and after known COVID-19 cases to identify candidate regions that are immunogenic and neutralizing. To
accomplish this aim, we will perform micro-neutralization assays (available in the BSL3 laboratory of Dr. Kristen
Bernard, UW Madison) on convalescent sera or nasal secretions from children who developed symptomatic
infection. This information will be analyzed together with pre- and post-infection array data using machine
learning approaches to identify neutralizing epitopes. Identifying patterns of serologic responses that are crossprotective could help to identify susceptible individuals in the population and direct the design of vaccines to
current and future viruses.
2019年12月开始的新型冠状病毒爆发造成了全球公共卫生紧急情况。这
导致了一个紧张的搜索,以确定因素,有助于易感性和疾病的严重性。我们
最近开发了一种阵列来鉴定鼻病毒的抗体结合表位。来自这些阵列的数据可以
结合有关病毒蛋白质结构的信息,以鉴定呼吸道感染的高免疫原性区域。
病毒我们建议扩展该阵列,以包括代表SARS-CoV-2和所有其他感染人类的常见冠状病毒(OC 43,NL 63等)的整个蛋白质组的线性表位。研究人群将
包括来自COAST、WISC和URECA出生队列研究的儿童,他们也参加了
HEROS SARS-CoV-2监测研究。作为常规队列活动的一部分,这些儿童接受系列
血液和鼻腔分泌物的采样,我们可以使用阵列进行分析,以确定
抗病毒抗体表位识别。我们假设,特异性抗体的模式和数量,
常见冠状病毒的表位有助于对SARS-CoV-2感染和疾病的易感性。我们
提出了三个具体目标,将利用从HEROS确认前后的儿童中获得的血清
感染了SARS-CoV-2首先,在感染前获得的标本中,我们将使用阵列来识别模式
识别常见儿童冠状病毒的抗体表位,评估与SARS-CoV-2的交叉反应性,
并确定交叉反应性是否与预防感染或疾病有关。在第二
目的:我们将确定对常见呼吸道病毒的抗体应答的多样性是否与
降低感染或患病的风险。最后,在第三个目标中,我们将描述抗体结合模式,
以及在已知的COVID-19病例之后,以鉴定具有免疫原性和中和性的候选区域。到
为了实现这一目标,我们将进行微量中和试验(可在Kristen博士的BSL 3实验室获得
Bernard,UW麦迪逊)对出现症状的儿童的恢复期血清或鼻分泌物进行了研究。
感染这些信息将与感染前和感染后的阵列数据一起使用机器进行分析
学习鉴定中和表位的方法。识别交叉保护的血清学应答模式有助于识别人群中的易感个体,并指导疫苗的设计,
当前和未来的病毒
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANN C. PALMENBERG其他文献
ANN C. PALMENBERG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANN C. PALMENBERG', 18)}}的其他基金
Identifying Coronavirus B-cell Epitopes Associated with COVID-19 Illness Severity
识别与 COVID-19 疾病严重程度相关的冠状病毒 B 细胞表位
- 批准号:
10201317 - 财政年份:2020
- 资助金额:
$ 40.35万 - 项目类别:
Molecular Biology of RV-C and its Asthma-related Receptor, CDHR3
RV-C 及其哮喘相关受体 CDHR3 的分子生物学
- 批准号:
10440067 - 财政年份:2013
- 资助金额:
$ 40.35万 - 项目类别:
COMPARATIVE MOLECULAR BIOLOGY AND GENOME STRUCTURE OF HRV-C
HRV-C 的比较分子生物学和基因组结构
- 批准号:
8469998 - 财政年份:2013
- 资助金额:
$ 40.35万 - 项目类别:
Molecular Biology of RV-C and its Asthma-related Receptor, CDHR3
RV-C 及其哮喘相关受体 CDHR3 的分子生物学
- 批准号:
10091396 - 财政年份:2013
- 资助金额:
$ 40.35万 - 项目类别:
Rhinovirus-Induced Shutoff of Cellular Responses
鼻病毒诱导的细胞反应关闭
- 批准号:
7151335 - 财政年份:2006
- 资助金额:
$ 40.35万 - 项目类别:
RELOCALIZATION OF CELLULAR PKR DURING MENGO VIRUS INFECTION
Mengo 病毒感染期间细胞 PKR 的重新定位
- 批准号:
6117330 - 财政年份:1998
- 资助金额:
$ 40.35万 - 项目类别:
RELOCALIZATION OF CELLULAR PKR DURING MENGO VIRUS INFECTION
Mengo 病毒感染期间细胞 PKR 的重新定位
- 批准号:
6278525 - 财政年份:1998
- 资助金额:
$ 40.35万 - 项目类别:
相似海外基金
Development of therapeutic monoclonal antibodies aiming at an application and the immunosuppression to an allergic disease of Fingolimod
针对芬戈莫德过敏性疾病的应用和免疫抑制的治疗性单克隆抗体的开发
- 批准号:
16K08409 - 财政年份:2016
- 资助金额:
$ 40.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Prevention of Allergic Rhinitis with Topical Immunomodulating Antibodies
使用外用免疫调节抗体预防过敏性鼻炎
- 批准号:
8201881 - 财政年份:2011
- 资助金额:
$ 40.35万 - 项目类别:
Development of antibodies to Il-13 receptor and their preclinical testing in a sheep model for human allergic asthma
IL-13受体抗体的开发及其在人类过敏性哮喘绵羊模型中的临床前测试
- 批准号:
nhmrc : 310603 - 财政年份:2004
- 资助金额:
$ 40.35万 - 项目类别:
Early Career Fellowships
B-1 B cells as a source of polyreactive IgE antibodies, in allergic individuals
B-1 B 细胞作为过敏个体中多反应性 IgE 抗体的来源
- 批准号:
nhmrc : 209590 - 财政年份:2002
- 资助金额:
$ 40.35万 - 项目类别:
NHMRC Project Grants
IgE antibodies to the mammalian oligosaccharide galactose-alpha-1, 3-galactose (alpha-gal): immunology, epidemiology and relevance to allergic and inflammatory disease
哺乳动物寡糖半乳糖-α-1, 3-半乳糖 (α-gal) 的 IgE 抗体:免疫学、流行病学以及与过敏性和炎症性疾病的相关性
- 批准号:
10518418 - 财政年份:1984
- 资助金额:
$ 40.35万 - 项目类别:
IgE antibodies to the mammalian oligosaccharide galactose-alpha-1, 3-galactose (alpha-gal): immunology, epidemiology and relevance to allergic and inflammatory disease
哺乳动物寡糖半乳糖-α-1, 3-半乳糖 (α-gal) 的 IgE 抗体:免疫学、流行病学以及与过敏性和炎症性疾病的相关性
- 批准号:
10119751 - 财政年份:1984
- 资助金额:
$ 40.35万 - 项目类别:
IgE antibodies to the mammalian oligosaccharide galactose-alpha-1, 3-galactose (alpha-gal): immunology, epidemiology and relevance to allergic and inflammatory disease
哺乳动物寡糖半乳糖-α-1, 3-半乳糖 (α-gal) 的 IgE 抗体:免疫学、流行病学以及与过敏性和炎症性疾病的相关性
- 批准号:
10425338 - 财政年份:1984
- 资助金额:
$ 40.35万 - 项目类别:
IgE antibodies to the mammalian oligosaccharide galactose-alpha-1, 3-galactose (alpha-gal): immunology, epidemiology and relevance to allergic and inflammatory disease
哺乳动物寡糖半乳糖-α-1, 3-半乳糖 (α-gal) 的 IgE 抗体:免疫学、流行病学以及与过敏性和炎症性疾病的相关性
- 批准号:
10190780 - 财政年份:1984
- 资助金额:
$ 40.35万 - 项目类别: